And Sarah. everybody joining for Thank thank today. me you, you
like started, language. you get we to I Harbor Before Safe would remind company’s of the
this assumptions. statements statements, objectives make we initiatives our and underlying strategies, plans, During including the and presentation, will regarding forward-looking
obtain listed that uncertainties statements are believe materially. limited actual to non-GAAP these available This in that risks earnings of made, our could measures the SEC comparable most and from reasonable necessary and that in to Reconciliation expectations with the These and adjusted call and forward-looking will such call relating to based include, our uncertainties included filings prior differ time-to-time conditions, environment products to to are new for into challenges growing are lines, site. cause statements maintain on these factors measures involve not the we approval, SEC our as demand filings. to, when our business non-GAAP economic are Web While services, general this EBITDA. to furnished forward-looking regulatory entering GAAP ability competitive release as the but financial present risks the consumer measures, risk and results and on and and the
we’ve ProPhase really company you our appreciate joining All statements out appreciate forward all and interest to that the in right, of now want looking me got you the way, welcome I Labs. your and
couple shoutouts. Just of quick
I First month. these per of that approximately called Renmark creates virtual all, work do non-deal roadshows. company we with a twice
our company, on evolving. interested constantly you in are If updates is our hearing company
company. dynamic a are We
in growing so areas. are many We different
is so going on much many We on. so are things. exciting There working
sign have if interested to with calls presentations to should presentations shareholders up up-to-date. keeping and remind you -- everyone are them, Renmark, contact so I up keep go find so feel out we VNDR. find and those that, also site. Web video we our out another And have I forth. when And are like I on free date, please in our through And slide
just the division significantly and two have is updated presentations. company One is that We our for was recently. presentation, biotech other
So I company in couple at just looked might the through update, of presentation haven't if want it, our think weeks. go last to you you
price per objective. So this Diamond $XX is of $XX go these H.C. site, our to I Web that having are are covered analysts just most and with stock a report by want money it Equity of updated recent four wealth Equity highlight, estimated research while has four All lose us from following objectives our to roughly dollars stock Diamond a to Wainwright, information. Confluence, Research. company to of really year, most Joshua now have recent $XX us share. The ThinkEquity, our we price companies Levine, also we
of people the awful COVID, is, an two bear going advantage for market shareholders. I assets, money which to think we the company, reason took on while company. you. believe lot multi-billion and or up future which for company we the an not to be year half year of in we is you to Anybody stock are an because underlying with earnings, wrong of advantage I was money. year. we of are highlight and the The got in invested that's the our took microcap we you that focused are us market you are stocks. this following and bear not or you a short while knew that's this making biotech always two the earnings going the We make But guess story have developing potential We a windfall unless opportunity was help for that dollar are point short But wonderful to
and we so underlying of with for fantastic value fantastic making money, our of our out acquisitions building And some company all the some were this future we while developing by planning technologies. were
not so I and We And term. doing always COVID the so. look COVID testing to testing, multi-billion that's build have spending the believe a that company. didn't two tell I long is infrastructure platform revenues. before. dollar generated destiny what have we been last years I it half people. that we have I now to and believe do my the
the what so it that gave opportunity. testing COVID did us And is
that also capital what we than and still we and point capital have and ago, to substantial businesses that we working COVID for and half capital the us lab would years and capital is build flu testing, that about we granted. business more years out lab And a raised the upper the and that two of minutes, developing subsidiaries I'm We CLIA now that CLIA are capital these they The ThinkEquity to to talk in for out coming other these respiratory two of in at did a take to with that when the going grow used thing with York I end day, all used we raised you not half all New the the ago. now.
with our and And so that of we protect of underlying the we our to behalf develop we on shareholders. here company I in ThinkEquity not dollar single and company shareholders executed the trust the value granted. Wainwright other us the and take a investment H.C. for bankers are do because and work that know
our underlying years now spent these but now. starting value right which other enormous only last these And potential some so we to generate are assets, not of them company have developing to significant
So there we have deferred our Nebula revenue. have the assets some in income it's focus acquisitions EBITDA, adjusted have in companies And quarter. between that on earned we with an first this of we significant are nice growing, terms because even sure story, again, lots of money be little -- value our options, stock with I'm we acquisitions of I adjusted earning net year is that time we EBITDA. of public a depreciate issues will expensing made, Genomics the expensing because this, not issues over while these versus issues
are these all issues. complicated there so And
focus to a had focused in like focused EBITDA on adjusted not the year not am EBITDA. I personally, adjusted first on EBITDA. number on the even We wonderful this earnings, quarter. adjusted I So I'm
that we're bet COVID business We in have our flu seasonally seasonally period particularly obviously, virtually can testing health and second time, slow You been the into testing, of to is public quarter. testing historically in weaker in. that Also, revenues, weaker a the as we're over. every going that's emergency going
we're earnings the people company. weaken read value So company to Renmark on to to -- to are but we're call you release numbers not on calls. this this again, the well. But just our our underlying want focused sure And mentioned press all building you, on earnings this this a most couple going I year, further. same relatively of of on expect I'm I'm certainly we're of morning I've that not release our focused can on make highlight. know the items going the to sure the page.
We have for a capacity demand. manufacturing facility enormous that is have which at we
the know a the brand. of The We of go are and important. selling this industry. of I turning from is view, supply and lozenge And point brand's Cold-EEZE retailers around well critically extremely reliability ballistic from thought in
generating after factor important the But to that then what If important forth, they their shelves they empty, most there buy, Walmart, second consumers that's most one factor -- on space. a a obviously. retailers carry profits they profitability. CVS want at all on to is on making the the that so inch want they're Walgreens, is buyers number product at times. want that's shelves The square and is having products based out It's are of to And the on shelf lose on. how that every these sure shelf reviews
a does retailers not it, on shelf there's when that So product have freak. literally the
issues there so lozenges the rather are a large globally. And is supply chain business, which in business
in have the coming we all brands, world want are largest us to some not the manufacturing, of to in so their but some manufacturing, us of only brands States and globally. of do want them us do to United their And the
this all extraordinary. food, in United for It's business So year. XXX% actually growing and originally place is exploding. a I almost business infrastructure we in kept primarily States. XX,XXX distribution mass the just storage a manufactured per is and the so that's that keep this to But touch potential a our drug facility
I've million we year to quickly capacity, $XX mentioned least we're and so. in revenues the of do to at out for how past think this year the is we which that have demand next going XXXX, constrained take by in I can just additional build
do with or company our year, some whether $XX business the so. there, of So market tens year. for right certainly, we're I Think that's call estimates developing, in to realistically, target of in next there's don't the think to of of reasonable manufacturing but this I be working that could facility. ongoing year And number equipment. be my kind relative And I'd million our this of number of All is theme like XXX% It's interesting earnings developing we're running head, but as millions is our manufacturing about million a dollars $XX facility our I even so million net and has then estimate that have right. no the $XX next now, up may an business to relative we market a worth that that's course, year a for the next could $XX of for And what during give enormous worth back least given this next over and out that. facility almost to year. or the company. have cap capital, $XX going year. say value to continue manufacturing year. nothing our million various be we cap well I million have already revenues do I've $XX are million assets guarantee,
COVID enough in lab. or that we any other testing a even have for our business business respiratory Forget or
tens Just the acquired the is of we've itself probably in of that equipment millions dollars.
we to esophageal our even So market get cancer almost about Genomics test. or our ever Linebacker compound without cap business, a Nebula thinking could cancer
business to or wanted clinical give just -- full lab I So building. you we're the
about those things. So few let's of talk a
testing We we've fully diversified our have clinical then also to genomic to it lab have state-of-the-art full lab. and a a diversified laboratory fully have
second our for half another abroad. the these until build We now, BXB we Right months take businesses then our business. will which we in those are the sequencing validations, year of aggressively we process cannot start will whole of We are a to with in-house. processing build and genome this out business couple specimens waiting specimens
So Nebula of anyway. year over second running building this the quarter. a year, half up revenues we In XXX% our Genomics the the particularly year fourth business are meantime, in very than anticipate nice more
million of some these businesses Genomics, probably businesses. and they We're Nebula are million that three understand And us. there whole yet, to other cost behind we businesses. sequencing $XX well situated, globally. of for the to these So States $XXX far years are five have provider situated, potentially similar United genomics are we genome ahead market in of and the caps startup And believe low that be
drug on CVS major right sequencing Walgreens store very whole to The again, direct of this the all half but And So of year. we to and will test doing in selling believe going now. the well. are retailers now, our I so know this consumers. don't point like only get Nebula business, at We're of looking tests several when, tests right second Genomics our that forth. we're shelves some the leverage and I business are -- genome
sequencing to of business. personalized the future I'm grow And the it's we the whole sequencing is And is, BXB then what research it expect future believe the genome in test. is but business provider to be of the it medicine, we cost heart that, this have at going to of that medicine of this going low country. explain not precision genome is and fantastic I rapidly. whole again
So already XXX% growing year-over-year. we are
if and is George Just renowned very advisory valuable of hockey ago, of our a our they just course have in a to University, in and of on regularly. forward them with to days that where questions Church, us a really We call in genomics is acceleration enormous was We retail involved I'm business introducing that's the to growth of stick BXB specific we experts, renowned is are looking imagine them is Altman you the the XX, field. Church further. business, talk world stores. Q&A, to this world addition It starts. course, happy Stanford from in And when just Russ it George Genomics. in They global Nebula us This are building Again, business have Internet helping ago. and about couple years I'm There genomics. players potential. had build the board. XX
We are so situated. well
I'm cancer everyone our then about so esophageal very test. excited And knows
In do blowing be we and cap next cancer potential cancer commercialized our have of really a we that fact, that market early kind the could the have has that esophageal mind it's literally of test we year test.
-- just interesting. $XX it's product there the -- was I is different They just cap. a have colon cancer. you just going Exact billion I'm for day, actually, which give a I first. other test a happened market a So has called to company note a Sciences Cologuard, called example
codes have We commercialize early test be a cancer. able believe are have We going to and our for CPT esophageal we next that test to year.
in just XX what I Exact cancer we're Sciences put if the our So test, want And company successful a be times as it's at our because theirs almost cancer that tests at apples-and-oranges, is, they colon in home. you perspective, of it are is that you. take esophageal it that when consumers our test and as it's for to just really today. value versus look put if XX% would to can perspective and test
Our our to tested, or all you to was we not sensitivity test at were XXX tell cancer. esophageal and specimens higher really going specificity. whether you It's higher test get remarkable In that has a test. the XXX accurate
that it’s to enormous, commercialize then just the this we test an it ramp potential studies is esophageal the know to and ones perspective cancer up looking looking what don't put but year. already for the I Sciences, in really of are And do done. We like we our next Exact the similar looks more are scary. to have
going out And institutional they I revenues to, on if weeks And on focused a to I wrong several the go back I And trip you into you are on in met that the few so investors. say again, focus Midwest that's focus earnings. ago why to it's are with silly and company. I and revenues. again, invested that, were did
on What from behalf yet value. of on I XX enormous have years building shareholders. two are been thing in last take half doing potential and have We is XX% companies assets stage is investing years. small now behalf of is This time the the execute and now. this my what And and this that have development I've what the executed for we develop managements of all on. we life The shareholders. cap done, have away don't done one you to are is right we dollar that is learned we execute the entire should again multi-billion I've
full can it want on our presentation subsidiaries. go Linebacker, about and Before and it the doesn't not they again, us. into But the were And we our for working going can of Q&A. turning and And selling detail have we too of hear the huge to a smaller if the now. you projects, I'll we're million, Cold-EEZE potential talk Huge. then that brand of XX open I'm where for was types much you win presentations activities to go then around for up sold on Renmark it to that each
offices get truly But including cancer not based excited the future. know, technologies but one you are at -- world, Linebacker It's scientist, talk in all on you States, we I about on working the He's professional Mayo or Linebacker, your We daily I'm on. And really that so we're so test him New test. continuing exciting more you're acquire Dhabi. in Clinic they actually Abu into excited compound And places also Chris excited. esophageal Clinic just I'll thing working ties developing and Mayo they're with in on about Dhabi, our Abu cancer esophageal they're thing York in single diligence, the actually doing have studies in unanimously medical every are biotech that our other on our United due when around in to do Dr. industry is and to you tell is the sorry, cancer have that about doctor, when is basis. what and we a as Hartley are the to almost another talk yourself. it's And can what results. you
esophageal we're just around with actually so Nebula in we the other be what of GERD to of And that out also Genomics it where about turns cancer, think than there's save it, States, in these initiatives So lives are and esophageal higher United the world? the there the so you are Linebacker, lives world. much. developed wouldn't developing in with States. around with MENA are our all the in if and And world, the such should cancer, Barrett’s parts incidents If esophagus going we're with save the the as region, United particular, why
just there's So potential. tremendous
fantastic I'm studies And the in so We to in Society. I we Linebacker, very results as and Harvard the further to positive the our shareholders Dana-Farber forward recently in And weeks did announced that looking studies regard Institute doing we're on coming getting was saying, with the initial Eurofins. Cancer updating we're with results. University that some analysis at
So there's talk there. to lot a about
day, token, And And I relates million example market some year I cancer test, so year, to $X $XXX results. our called the on with fact went a I BMEA, interesting. $X that Linebacker, perspective it's by the in value developing $XX us market from because that $XXX Over in X over dollars. their one over put that increased to how in positive company Phase happened same went from was million. cap billion the by other there's esophageal this potentially while notice gave to stocking day, last Sciences Biomea Exact of just Fusion, and to the
If million we now had was $XX. of a was argue You is And It $XXX market that $X cap, year same market type times dollar developing cap, with now market $X XX efficient, it's potential. always this are year. assets the stock to efficient? in has but the billion market want the one ago,
So market relative do really cap earnings. This of year. I to we're and shareholders I revenues want the want developing the know suggestion our cap. don't on dwarf potential is a stock investors used follow the if is word we're press have that today. that continue less stock. rewarded that I in the that's our that underlying assets term is to but our market will well I be focus the on price, assets of company. my long focus value, enormous let Focus value believe release building, to because you transition underlying the And on our And our why, to transition I believe, to
I our good perspective hope I'm Q&A. so for today. bit me just just to. there another want questions into not And again, some questions gives these some subsidiaries. sure hour. how an of thank going that all And And I'm to and out to are we that obviously be can I'm little get hour, are on could you there a I joining more there various some details thinking. another talk I for in on you half going
like So hand it Sarah, to I to with over that, would questions. you for
